GlaxoSmithKline plc - Asset Resilience Ratio
GlaxoSmithKline plc (GSKN) has an Asset Resilience Ratio of 0.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GSKN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how GlaxoSmithKline plc's Asset Resilience Ratio has changed over time. See GlaxoSmithKline plc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down GlaxoSmithKline plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GSKN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$10.00 Million | 0.02% |
| Total Liquid Assets | MX$10.00 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: GlaxoSmithKline plc maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GlaxoSmithKline plc Industry Peers by Asset Resilience Ratio
Compare GlaxoSmithKline plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Annual Asset Resilience Ratio for GlaxoSmithKline plc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.04% | MX$21.00 Million ≈ $1.21 Million |
MX$59.46 Billion ≈ $3.42 Billion |
-3.77pp |
| 2023-12-31 | 3.81% | MX$2.25 Billion ≈ $129.26 Million |
MX$59.01 Billion ≈ $3.40 Billion |
-3.10pp |
| 2022-12-31 | 6.91% | MX$4.15 Billion ≈ $239.06 Million |
MX$60.15 Billion ≈ $3.46 Billion |
+6.83pp |
| 2021-12-31 | 0.08% | MX$61.00 Million ≈ $3.51 Million |
MX$79.10 Billion ≈ $4.55 Billion |
-0.02pp |
| 2020-12-31 | 0.10% | MX$78.00 Million ≈ $4.49 Million |
MX$80.43 Billion ≈ $4.63 Billion |
0.00pp |
| 2019-12-31 | 0.10% | MX$79.00 Million ≈ $4.55 Million |
MX$79.69 Billion ≈ $4.59 Billion |
-0.05pp |
| 2018-12-31 | 0.14% | MX$84.00 Million ≈ $4.83 Million |
MX$58.07 Billion ≈ $3.34 Billion |
+0.01pp |
| 2017-12-31 | 0.14% | MX$78.00 Million ≈ $4.49 Million |
MX$56.38 Billion ≈ $3.24 Billion |
-0.01pp |
| 2016-12-31 | 0.15% | MX$89.00 Million ≈ $5.12 Million |
MX$59.08 Billion ≈ $3.40 Billion |
+0.01pp |
| 2015-12-31 | 0.14% | MX$75.00 Million ≈ $4.32 Million |
MX$53.45 Billion ≈ $3.08 Billion |
-0.03pp |
| 2014-12-31 | 0.17% | MX$69.00 Million ≈ $3.97 Million |
MX$40.65 Billion ≈ $2.34 Billion |
+0.01pp |
| 2013-12-31 | 0.16% | MX$66.00 Million ≈ $3.80 Million |
MX$42.09 Billion ≈ $2.42 Billion |
-- |
About GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more